ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0129

Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)
Abstract Number: 0130

Association of HLA-DRB1 Alleles with Coronary Artery Calcium, Abdominal Aortic Calcium, and Carotid Intima-media Thickness in a Multi-ethnic Community-living Population
Abstract Number: 0131

Identifying Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease: Development and Validation of a Real-Time Risk Model
Abstract Number: 0132

Feasibility of a Real-Time Risk Model to Identify Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease
Abstract Number: 0133

COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study
Abstract Number: 0134

Stressful Life Events in the Year Prior to Their Diagnosis Are Associated with Adult and Pediatric Systemic Rheumatic Diseases
Abstract Number: 0135

Cancer Incidence and Risk Factors in Patients with Newly Diagnosed Systemic Lupus Erythematosus
Abstract Number: 0136

The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-term Hydroxychloroquine Use
Abstract Number: 0137

Incidence of and Risk Factors for Myelodysplastic Syndromes in Patients with Rheumatologic Diseases
Abstract Number: 0138

Prevalence and Incidence of Sjögren’s Syndrome: A Systematic Literature Review
Abstract Number: 0139

Systemic Vasculitides in Portugal and Brazil: Preliminary Results from the Reuma.pt/vasculitis Registry
Abstract Number: 0140

Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database
Abstract Number: 0141

In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis
Abstract Number: 0142

New-Onset Systemic Autoimmune Diseases Following COVID-19 Vaccination – Results from the COVAD Study
Abstract Number: 0143

Cancer Incidence in Familial Mediterranean Fever

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].